Boehringer anti-clotting drug performs in Phase III

The race for a new anti-clotting therapy turned even hotter today as Boehringer Ingelheim announced that a late-stage study of its once daily pill dabigatran showed that the therapy is as effective as Lovenox injections for preventing blood clots after hip surgery. Boehringer has positioned the drug against Bayer's rivaroxaban, which demonstrated superiority to Lovenox after knee surgery. The clotting development race began after AstraZeneca failed to gain an approval for Exanta in 2004.

- see the release for more

Related Articles:
Pfizer, BMS report Phase II clotting trial success. Report
TransTech inks deal with Boehringer. Report
Boehringer wins Aptivus OK. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.